Literature DB >> 27133539

Sequential Serum Let-7 Is a Novel Biomarker to Predict Accelerated Reproliferation During Fractional Radiotherapy in Lung Cancer.

Peng Xie1, Xiaolin Li2, Xuefen Tan3, Xindong Sun2, Chungang Wang4, Jinming Yu5.   

Abstract

BACKGROUND: Accelerated reproliferation, usually deemed to occur late during the course of radiation therapy, is an important factor resulting in radiotherapy failure. The identification of strategies that accurately reflect accelerated reproliferation might help to determine radiotherapy strategy, and thus implementation of individualized treatment. PATIENTS AND METHODS: Patients with lung cancer were enrolled from Shandong Cancer Hospital and Institute in China between March 2014 and March 2015. Tumor tissue and sequential peripheral blood samples were obtained before treatment and during radiotherapy to detect Ki-67 and let-7 expression.
RESULTS: We found a strong correlation between serum let-7 and tissue Ki-67 before treatment (r = -0.773; P = .003). Patients with a high level of baseline serum let-7 expression level had significantly better overall survival (the overall survival were 100% and 27.3%, respectively; P = .024). For patients with a relatively low expression level of baseline serum let-7, there was a peak of expression levels at week 4 (the mean expression levels were 1.40, 5.01, and 1.36, respectively). However, for patients with relatively high expression levels of baseline serum let-7, the expression levels were constantly downregulated at week 4 and 6 compared with the original (the mean expression levels were 6.16 vs. 1.34 vs. 0.80, respectively).
CONCLUSION: The study showed that serum let-7 expression level could reflect the proliferation of tumor tissue reliably in patients with lung cancer. Furthermore, the study might change conventional views of accelerated reproliferation. We showed that initial accelerated proliferation exists in patients with a relatively slow proliferation rate before radiotherapy, and late course accelerated reproliferation exists in patients with relatively fast proliferation before radiotherapy.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bronchogenic; Carcinoma; MicroRNA; Prognosis; Proliferation; Radiation

Mesh:

Substances:

Year:  2016        PMID: 27133539     DOI: 10.1016/j.cllc.2016.03.010

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


  9 in total

Review 1.  Circulating miRNAs as Diagnostic and Prognostic Biomarkers in Common Solid Tumors: Focus on Lung, Breast, Prostate Cancers, and Osteosarcoma.

Authors:  Michela Bottani; Giuseppe Banfi; Giovanni Lombardi
Journal:  J Clin Med       Date:  2019-10-11       Impact factor: 4.241

Review 2.  Liquid biopsy for early stage lung cancer.

Authors:  Wenhua Liang; Yi Zhao; Weizhe Huang; Hengrui Liang; Haikang Zeng; Jianxing He
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

3.  Clinical value of exhaled breath condensate let-7 in non-small cell lung cancer.

Authors:  Jin-Liang Chen; Hui-Na Han; Xue-Dong Lv; Hang Ma; Jin-Nan Wu; Jian-Rong Chen
Journal:  Int J Clin Exp Pathol       Date:  2020-02-01

4.  Properties and gene expression profiling of acquired radioresistance in mouse breast cancer cells.

Authors:  Feng Qin; Qiang Fan; Peter K N Yu; Waleed Abdelbagi Almahi; Peizhong Kong; Miaomiao Yang; Wei Cao; Lili Nie; Guodong Chen; Wei Han
Journal:  Ann Transl Med       Date:  2021-04

Review 5.  Radiotherapy resistance: identifying universal biomarkers for various human cancers.

Authors:  Irina Larionova; Militsa Rakina; Elena Ivanyuk; Yulia Trushchuk; Alena Chernyshova; Evgeny Denisov
Journal:  J Cancer Res Clin Oncol       Date:  2022-02-03       Impact factor: 4.322

6.  Ratio of Autoantibodies of Tumor Suppressor AIMP2 and Its Oncogenic Variant Is Associated with Clinical Outcome in Lung Cancer.

Authors:  Ji Ye Jung; Eun Young Kim; Arum Kim; Joon Chang; Nam Hoon Kwon; Youngji Moon; Eun Joo Kang; Jun Sik Sung; Hyunbo Shim; Sunghoon Kim; Yoon Soo Chang
Journal:  J Cancer       Date:  2017-05-12       Impact factor: 4.207

Review 7.  Tissue-specific and exosomal miRNAs in lung cancer radiotherapy: from regulatory mechanisms to clinical implications.

Authors:  Long Long; Xue Zhang; Jian Bai; Yizhou Li; Xiaolong Wang; Yunfeng Zhou
Journal:  Cancer Manag Res       Date:  2019-05-13       Impact factor: 3.989

Review 8.  Let-7 as biomarker, prognostic indicator, and therapy for precision medicine in cancer.

Authors:  Evgeny Chirshev; Kerby C Oberg; Yevgeniya J Ioffe; Juli J Unternaehrer
Journal:  Clin Transl Med       Date:  2019-08-28

Review 9.  The dawn of the liquid biopsy in the fight against cancer.

Authors:  Irma G Domínguez-Vigil; Ana K Moreno-Martínez; Julia Y Wang; Michael H A Roehrl; Hugo A Barrera-Saldaña
Journal:  Oncotarget       Date:  2017-12-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.